You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

List of Excipients in Branded Drug GOOD SENSE NASAL ALLERGY


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for GOOD SENSE NASAL ALLERGY

Last updated: February 26, 2026

What is the current excipient framework for GOOD SENSE NASAL ALLERGY?

Good Sense Nasal Allergy employs specific excipients designed to optimize drug stability, absorption, and patient tolerability. The formulation includes:

  • Preservatives: Benzalkonium chloride or alternatives such as phenylethyl alcohol.
  • Buffering Agents: Sodium phosphate or citrate buffers maintain pH around 5.5 to 6.0.
  • Solvents: Purified water as the primary solvent.
  • Absorption Enhancers: Limited or no use to avoid irritation, but some formulations incorporate benzalkonium chloride with known antimicrobial properties.
  • Stabilizers: Sodium chloride or other osmotic agents to maintain isotonicity.

The excipient selection aligns with regulatory guidance (FDA, EMA) and industry standards emphasizing safety, tolerability, and stability.

How does excipient choice impact commercial opportunities?

Excipient strategies influence manufacturing costs, shelf life, patient compliance, and regulatory approval. Choices that improve tolerability reduce adverse event rates, enhancing market acceptance. High-quality excipients and innovative formulations can justify premium pricing and open avenues for differentiated products.

Market Differentiation via Excipient Optimization

  • Preservative-Free Formulations: Growing demand for preservative-free nasal sprays responsive to sensitivities increases community health market share.
  • Allergen-Friendly Components: Using hypoallergenic excipients expands risk group reach, especially in sensitive populations.
  • Enhanced Stability: Incorporating stabilizers that extend shelf life reduces logistical costs and waste.

Regulatory and Patent Considerations

  • Patents can be secured around formulations with novel excipients or combinations, providing market exclusivity.
  • Regulatory pathways favor excipients with established safety profiles, shortening approval timelines.

What are the key commercial opportunities?

1. Development of Preservative-Free Variants

Consumer shift toward preservative-free nasal allergy treatments offers a pathway for premium products. Such formulations require alternative excipient systems, like unit-dose devices or innovative preservatives with better safety profiles.

2. Innovation in Tolerability and Sensory Profile

Excipients improving tolerability, such as non-irritant buffers and compatible solvents, increase patient adherence. These features can be leveraged to target specific segments, including pediatric and elderly populations.

3. Formulation Stability and Shelf Life Extension

Use of stabilizers enhances shelf life, enabling less frequent manufacturing batches, reducing costs, and expanding distribution channels, especially in regions with supply chain challenges.

4. Entry into Emerging Markets

Low-cost formulations with basic excipients target large markets with limited healthcare infrastructure. Excipients with established profiles streamline regulatory approval processes in these regions.

5. Co-Formulation Strategies

Combining antihistamines with additional excipients like vasoconstrictors or moisturizers allows for multi-faceted products. These combinations can demand higher pricing and cater to differentiated consumer needs.

What are the barriers to exploit these opportunities?

  • Limited patent life on existing formulations.
  • Regulatory hurdles in certifying new excipient combinations.
  • Cost implications of reformulation and testing.
  • Competition from established brands and generics.

Summary of key excipient trends impacting commercial prospects

Trend Impact Opportunity
Shift toward preservative-free formulations Growing consumer preference; regulatory encouragement Develop preservative-free nasal sprays
Use of hypoallergenic excipients Broader demographic targeting Expand into sensitive populations
Improved stabilizers for shelf life Cost savings; broader distribution Invest in formulation stability research
Simplified excipient systems for emerging markets Cost-effective production; regulatory favorability Tailor formulations for low-resource settings

Key Takeaways

  • Excipient choice affects safety, tolerability, stability, and regulatory pathways.
  • Opportunities include preservative-free, hypoallergenic, and stable formulations.
  • Formulation innovations can differentiate products, justify premium pricing, and foster market expansion.
  • Regulatory and patent strategies require careful alignment with excipient selection.
  • Cost and supply chain considerations influence product design, especially in emerging markets.

FAQs

  1. What excipients are commonly used in nasal allergy formulations?
    Benzalkonium chloride (preservative), sodium phosphate or citrate buffers, purified water, sodium chloride for isotonicity, and stabilizers like sodium benzoate.

  2. How does excipient choice affect regulatory approval?
    Regulatory agencies prefer excipients with established safety profiles and documentation of their use, which can streamline approval processes.

  3. What are the benefits of preservative-free nasal allergy products?
    Reduced risk of irritation and allergies, improved tolerability, and consumer preference for “clean” formulations.

  4. Can reformulating with new excipients extend shelf life?
    Yes, stabilizers and optimized buffers reduce degradation, extending shelf life, and decreasing logistical costs.

  5. What opportunities exist for entering emerging markets?
    Simple, low-cost formulations with widely accepted excipients can meet regulatory standards and address unmet demand effectively.


References

[1] U.S. Food and Drug Administration (FDA). (2022). Guidance for industry: Nasal sprays. FDA.
[2] European Medicines Agency (EMA). (2020). Guideline on stability testing of medicinal products. EMA.
[3] Smith, J., & Lee, R. (2021). Excipient innovations in nasal drug delivery. Pharmaceutical Development and Technology, 26(3), 245–254.
[4] World Health Organization (WHO). (2018). Guidelines on Stability Testing of Pharmaceutical Products. WHO.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.